KRN7000

MHC ligand



BML-SL232-0100	100 µg	270.00 USD

BML-SL232-1000	1 mg	915.00 USD

Replaces Prod. #: ALX-306-027

KRN7000 is a synthetic analog of α-galactosylceramide and the marine natural product agelasphin. It is a specific ligand for human and mouse NKT cells and remains the best studied ligand of the lipid-binding MHC class I-like protein CD1d. It protects against LPS-induced shockand displays potent antitumor activity in various in vivo models.

Product Specification

Alternative Name:	α-Galactosylceramide, (2S,3S,4R)-1-O-(α-D-Galactosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol

Formula:	C₅₀H₉₉NO₉

MW:	858.3

Purity:	≥99% (HPLC)

Appearance:	White solid.

CAS:	158021-47-7

Solubility:	Soluble in: 0.2mg/ml PBS containing 0.5% Tween-20 (sonicate 2 hrs. at 37°C).

Long Term Storage:	-20°C

Use/Stability:	Store solutions at -20°C for up to 3 months.

Background / Technical Information:	Please click here for the comprehensive product datasheet.

Please mouse over

Product Literature References

Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments: M. Moll, et al.; Blood in press, (2010), Abstract;

Invariant valpha14 natural killer T cell activation by edible mushroom acidic glycosphingolipids: H. Nozaki, et al.; Biol. Pharm. Bull. 33, 580 (2010), Abstract;

Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock: G. Sireci, et al.; J. Leukoc. Biol. 81, 607 (2007), Abstract;

Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d: K.O. Yu, et al.; J. Immunol. Methods 323, 11 (2007), Abstract;

A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer: A. Ishikawa, et al.; Clin. Cancer Res. 11, 1910 (2005), Abstract;

Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides: K.O. Yu, et al.; PNAS 102, 3383 (2005), Abstract;